Lisa Derosa

16.5k total citations · 1 hit paper
111 papers, 3.2k citations indexed

About

Lisa Derosa is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Molecular Biology. According to data from OpenAlex, Lisa Derosa has authored 111 papers receiving a total of 3.2k indexed citations (citations by other indexed papers that have themselves been cited), including 65 papers in Oncology, 64 papers in Pulmonary and Respiratory Medicine and 36 papers in Molecular Biology. Recurrent topics in Lisa Derosa's work include Cancer Immunotherapy and Biomarkers (39 papers), Renal cell carcinoma treatment (34 papers) and Gut microbiota and health (22 papers). Lisa Derosa is often cited by papers focused on Cancer Immunotherapy and Biomarkers (39 papers), Renal cell carcinoma treatment (34 papers) and Gut microbiota and health (22 papers). Lisa Derosa collaborates with scholars based in France, Italy and Canada. Lisa Derosa's co-authors include Laurence Zitvogel, Bertrand Routy, Guido Kroemer, Bernard Escudier, Laurence Albigès, Arielle Elkrief, Bertrand Routy, Marine Fidelle, Matthew D. Hellmann and Luca Galli and has published in prestigious journals such as Nature Medicine, Journal of Clinical Oncology and PLoS ONE.

In The Last Decade

Lisa Derosa

106 papers receiving 3.2k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Negative association of antibiotics on clinical activity of immune checkpoint inhibitors in patients with advanced renal cell and non-small-cell lung cancer

2018 631 citations Lisa Derosa, Laurence Zitvogel et al. Annals of Oncology profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Lisa Derosa France	25	1.7k	1.3k	1.0k	415	345	111	3.2k
Tadashi Mio Japan	33	1.7k 1.0×	653 0.5×	1.9k 1.9×	364 0.9×	209 0.6×	156	3.8k
David D. Hurd United States	35	1.6k 0.9×	1.2k 0.9×	457 0.5×	325 0.8×	196 0.6×	159	4.8k
Raghunadharao Digumarti India	25	2.4k 1.4×	1.1k 0.9×	2.5k 2.5×	551 1.3×	601 1.7×	150	5.1k
Alan S. Gamis United States	41	1.1k 0.6×	1.6k 1.2×	320 0.3×	377 0.9×	180 0.5×	222	5.0k
Choon‐Taek Lee South Korea	33	839 0.5×	687 0.5×	2.0k 2.0×	445 1.1×	395 1.1×	138	3.5k
Soichiro Yokota Japan	27	2.0k 1.1×	800 0.6×	1.7k 1.7×	172 0.4×	229 0.7×	96	3.4k
Antonio Ghidini Italy	27	1.4k 0.8×	435 0.3×	695 0.7×	362 0.9×	85 0.2×	91	2.3k
Dorothea Nagel Germany	41	1.2k 0.7×	1.2k 0.9×	568 0.6×	974 2.3×	117 0.3×	86	3.9k
Young Whan Kim South Korea	34	810 0.5×	557 0.4×	1.7k 1.7×	253 0.6×	538 1.6×	176	3.4k
Jing Jiang China	37	1.1k 0.7×	1.2k 0.9×	919 0.9×	1.3k 3.2×	141 0.4×	160	4.5k

Countries citing papers authored by Lisa Derosa

Since Specialization

Citations

This map shows the geographic impact of Lisa Derosa's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Lisa Derosa with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Lisa Derosa more than expected).

Fields of papers citing papers by Lisa Derosa

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Lisa Derosa. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Lisa Derosa. The network helps show where Lisa Derosa may publish in the future.

Co-authorship network of co-authors of Lisa Derosa

This figure shows the co-authorship network connecting the top 25 collaborators of Lisa Derosa. A scholar is included among the top collaborators of Lisa Derosa based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Lisa Derosa. Lisa Derosa is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Silva, Carolina Alves Costa, Nerina Denaro, Matteo Lambertini, et al.. (2025). The interplay between gut microbiota, antibiotics, and immune checkpoint inhibitors in patients with cancer: A narrative review with biological and clinical aspects. Critical Reviews in Oncology/Hematology. 212. 104767–104767. 1 indexed citations

Zitvogel, Laurence, Lisa Derosa, Bertrand Routy, et al.. (2025). Impact of the ONCOBIOME network in cancer microbiome research. Nature Medicine. 31(4). 1085–1098. 7 indexed citations

Belluomini, Lorenzo, Francesca Gattazzo, Caroline Flament, et al.. (2024). 1172O Akkermansia muciniphila-based multi-omic profiling in advanced non-small cell lung cancer. Annals of Oncology. 35. S762–S762. 1 indexed citations

Reni, Anna, Caroline Flament, Lorenzo Belluomini, et al.. (2024). Impact of microbiota specific circulating memory T cells in response to immunotherapy.. Journal of Clinical Oncology. 42(16_suppl). 2572–2572. 3 indexed citations

Ferrere, Gladys, et al.. (2024). 804MO Gut microbiota composition is predictive of CAR-T cells response and its modulation enhances CAR-T cells activity. Annals of Oncology. 35. S598–S598.

Marmorino, Federica, Gianmarco Piccinno, Daniele Rossini, et al.. (2023). Gut microbiome composition as predictor of the efficacy of adding atezolizumab to first-line FOLFOXIRI plus bevacizumab in metastatic colorectal cancer: A translational analysis of the AtezoTRIBE study.. Journal of Clinical Oncology. 41(16_suppl). 3534–3534. 2 indexed citations

Goubet, Anne‐Gaëlle, Mathieu Rouanne, Lisa Derosa, Guido Kroemer, & Laurence Zitvogel. (2023). From mucosal infection to successful cancer immunotherapy. Nature Reviews Urology. 20(11). 682–700. 9 indexed citations

Colomba, Émeline, Carolina Alves Costa Silva, Gwénaël Le Teuff, et al.. (2022). Weight and skeletal muscle loss with cabozantinib in metastatic renal cell carcinoma. Journal of Cachexia Sarcopenia and Muscle. 13(5). 2405–2416. 8 indexed citations

Derosa, Lisa, Bertrand Routy, Antoine Desîlets, et al.. (2021). Microbiota-Centered Interventions: The Next Breakthrough in Immuno-Oncology?. Cancer Discovery. 11(10). 2396–2412. 100 indexed citations

10.

Hakozaki, Taiki, Corentin Richard, Arielle Elkrief, et al.. (2020). The Gut Microbiome Associates with Immune Checkpoint Inhibition Outcomes in Patients with Advanced Non–Small Cell Lung Cancer. Cancer Immunology Research. 8(10). 1243–1250. 216 indexed citations

11.

Liu, Peng, Liwei Zhao, Gladys Ferrere, et al.. (2020). Combination treatments with hydroxychloroquine and azithromycin are compatible with the therapeutic induction of anticancer immune responses. OncoImmunology. 9(1). 1789284–1789284. 4 indexed citations

12.

Huang, Jinfeng, Jianfei Shen, Xiao Li, et al.. (2020). Incidence of patients with bone metastases at diagnosis of solid tumors in adults: a large population-based study. Annals of Translational Medicine. 8(7). 482–482. 131 indexed citations

13.

Massari, Francesco, Vincenzo Di Nunno, Annalisa Guida, et al.. (2020). Addition of Primary Metastatic Site on Bone, Brain, and Liver to IMDC Criteria in Patients With Metastatic Renal Cell Carcinoma: A Validation Study. Clinical Genitourinary Cancer. 19(1). 32–40. 21 indexed citations

14.

Flippot, Ronan, Lisa Derosa, & Laurence Albigès. (2018). Les métastases cérébrales de cancer du rein, un défi clinique. Bulletin du Cancer. 105. S261–S267. 1 indexed citations

15.

Grassi, Paolo, Ludovic Doucet, Viktor Grünwald, et al.. (2017). Outcome of Patients with Renal Cell Carcinoma and Multiple Glandular Metastases Treated with Targeted Agents. Oncology. 92(5). 269–275. 3 indexed citations

16.

Guida, Annalisa, Laurence Albigès, Lisa Derosa, et al.. (2017). Everolimus Versus Axitinib as Second-line Therapy in Metastatic Renal Cell Carcinoma: Experience From Institut Gustave Roussy. Clinical Genitourinary Cancer. 15(6). e1081–e1088. 4 indexed citations

17.

Re, Marzia Del, Elisa Biasco, Stefania Crucitta, et al.. (2016). AR-V7 detection in plasma-derived exosomal RNA strongly predicts resistance to hormonal therapy in metastatic prostate cancer. Annals of Oncology. 27. vi248–vi248. 1 indexed citations

18.

Re, Marzia Del, Elisa Biasco, Stefania Crucitta, et al.. (2016). The Detection of Androgen Receptor Splice Variant 7 in Plasma-derived Exosomal RNA Strongly Predicts Resistance to Hormonal Therapy in Metastatic Prostate Cancer Patients. European Urology. 71(4). 680–687. 224 indexed citations

19.

Derosa, Lisa, Annalisa Guida, Laurence Albigès, et al.. (2015). New prognostic factors for second-line targeted therapy (TT) in metastatic renal cell carcinoma (mRCC). Annals of Oncology. 26. vi53–vi53. 1 indexed citations

20.

Derosa, Lisa, et al.. (1964). [DESCRIPTION OF A NEW SLOW HEMOGLOBIN IN A CASERTIAN FAMILY (HB CASERTA)].. PubMed. 20. 157–62. 1 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact